Marketed for longevity and wellness benefits, the unproven therapies are sold through a grey market online. Compounding ...
Cemdisiran, a potential new drug for the treatment of generalized myasthenia gravis, has been accepted for priority review by ...
After debuting on the public markets with $256.3 million and raking in an additional $472 million, Veradermics has emerged as one of biotech’s biggest post-IPO standouts. CEO Reid Waldman credits the ...
Significant leadership instability at the FDA—compounded by continued workforce attrition—led to a slight slowdown in overall regulatory productivity in the first half of this year, but the agency has ...
The United States Food and Drug Administration (USFDA) has issued a warning letter to Hyderabad-based online retailer ...
OpenDDE is a preview release. CLI flags, input/output JSON fields, and released checkpoints may change between versions, and predictions are not guaranteed to be reproducible across releases. It is ...
As the World Cup has captured the attention of viewers around the globe, so has the Food and Drug Administration (FDA) when it comes to ...
As radiopharmaceutical therapy (RPT) expands beyond neuroendocrine tumors and prostate cancer, it is important to understand ...
The U.S. FDA has sent a new batch of warning letters to telehealth firms that allegedly made false and misleading claims about low-cost compounded versions of GLP-1 drugs, the popular class of ...
Social media users claimed thieves used drugged perfume to knock women out and rob them.
The operational structure of the FDA around centers, each governing a particular regulatory or scientific area, dates back more than 40 years. It remains intact for now, but Rick Pazdur, former ...
WASHINGTON, May 15 (Reuters) - The acting head of the U.S. Food and Drug Administration's drug center, Tracy Beth Hoeg, is expected to leave the agency just days after Commissioner Marty Makary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results